Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.

Hyperprolactinemia Macroprolactinemia Pitfalls Prolactin

Journal

Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665

Informations de publication

Date de publication:
2019
Historique:
received: 13 12 2018
accepted: 17 03 2019
pubmed: 20 3 2019
medline: 7 5 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

An appropriate diagnostic evaluation is essential for the most appropriate treatment to be performed. Currently, macroprolactinemia is the third most frequent cause of nonphysiological hyperprolactinemia after drugs and prolactinomas. Up to 40% of macroprolactinemic patients may present with hypogonadism symptoms, infertility, and/or galactorrhea. Thus, the screening for macroprolactin is indicated not only for asymptomatic subjects but also for those without an obvious cause for their prolactin (PRL) elevation. Before submitting patients to macroprolactin screening and pituitary magnetic resonance imaging, one should rule out pregnancy, drug-induced hyperprolactinemia, primary hypothyroidism, and renal failure. The magnitude of PRL elevation can be useful in determining the etiology of hyperprolactinemia. PRL values >250 ng/mL are highly suggestive of prolactinomas and virtually exclude nonfunctioning pituitary adenomas (NFPAs) and other sellar masses as the etiology of hyperprolactinemia. However, they can also be found in subjects with macroprolactinemia, drug-induced hyper-prolactinemia or chronic renal failure. By contrast, most patients with NFPAs, drug-induced hyperprolactinemia, macroprolactinemia, or systemic diseases present with PRL levels <100 ng/mL. However, exceptions to these rules are not rare. Indeed, up to 25% of patients harboring a microprolactinoma or a cystic macroprolactinoma may also have PRL <100 ng/mL. Falsely low PRL levels may result from the so-called "hook effect," which should be considered in all cases of large (≥3 cm) pituitary adenomas associated with normal or mildly elevated PRL levels (≤250 ng/mL). The hook effect may be unmasked by repeating PRL measurement after a 1:100 serum sample dilution.

Identifiants

pubmed: 30889571
pii: 000499694
doi: 10.1159/000499694
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-19

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Lucio Vilar (L)

Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil, lvilarf@gmail.com.
Pernambuco Endocrine Research Center, Recife, Brazil, lvilarf@gmail.com.

Clarice Freitas Vilar (CF)

Pernambuco Endocrine Research Center, Recife, Brazil.

Ruy Lyra (R)

Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil.

Maria da Conceição Freitas (MDC)

Pernambuco Endocrine Research Center, Recife, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH